Challenges of Anticoagulant Therapy in Atrial Fibrillation-Focus on Gastrointestinal Bleeding

Area of Science:

• Cardiology
• Pharmacology
• Clinical Medicine

Background:

• Atrial fibrillation (AF) prevalence is rising, presenting significant clinical challenges in stroke prevention and anticoagulant management.
• Direct oral anticoagulants (DOACs) are preferred over warfarin for AF stroke prevention due to ease of use, but bleeding risk assessment remains difficult.
• Gastrointestinal bleeding (GIB) is a concern with anticoagulants; warfarin dose adjustment triples GIB risk, and DOACs may increase GIB compared to warfarin.

Purpose of the Study:

• To comprehensively review bleeding risks associated with oral anticoagulant therapy in AF patients.
• To highlight recent findings on GIB in oral anticoagulation and identify knowledge gaps.
• To pinpoint areas for future research in anticoagulant-related bleeding.

Main Methods:

• Literature review focusing on bleeding risk, GIB, and oral anticoagulant therapy in AF.
• Analysis of current guidelines and evidence regarding DOACs and warfarin.
• Identification of unmet needs in bleeding risk stratification.

Main Results:

• DOACs are recommended for AF stroke prevention, but accurate bleeding risk scores, especially for GIB, are lacking.
• While overall bleeding risk may be lower with DOACs, they are associated with increased GIB compared to warfarin.
• Current bleeding risk assessment relies on general factors, with unknown individual contributions.

Conclusions:

• Accurate, DOAC-specific bleeding risk scores are essential for safe and effective anticoagulant therapy in AF patients.
• Further research is needed to understand and mitigate GIB risk associated with DOACs.
• Improved risk assessment tools are crucial for optimizing stroke prevention while minimizing bleeding complications in AF.